- •Unique case of MOG-EM and lung cancer in a patient with intracranial lesions.
- •MOG-IgG detected in serum and CSF; patient was successfully treated with steroids.
- •Implications for early detection of MOG-IgG to avoid treatment delays.
Myelin oligodendrocyte glycoprotein (MOG) is an important marker on the surface of oligodendrocytes and is associated with many demyelinating diseases. Recently, MOG-IgG-associated encephalomyelitis (MOG-EM) has been proposed as a disease entity with a preliminary diagnosis standard. Some patients with lung cancer have been reported to be seropositive for onconeural antibodies; however, lung cancer cases with MOG-EM have not been previously reported.
We report the case of a patient with lung adenocarcinoma with multiple intracranial lesions found during molecular targeted therapy.
The patient tested positive for MOG antibody in her cerebrospinal fluid, and the therapeutic effect of steroids was excellent.
This is the first reported case of MOG-EM coincident with lung cancer in a patient with multiple intracranial lesions. When patients present with a history of malignant tumors or suspected paraneoplastic neurological syndrome, clinicians should also be alert to the presence of other autoimmune antibodies such as MOG-IgG to avoid treatment delay.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Cerebral cortical encephalitis followed by recurrent CNS demyelination in a patient with concomitant anti-MOG and anti-NMDA receptor antibodies.Mult. Scler. Relat. Disord. 2017; 18: 90-92
Jarius, S., et al., [MOG encephalomyelitis: international recommendations on diagnosis and antibody testing].Nervenarzt, 2018.89 (12): p. 1388–1399.
- Recommended diagnostic criteria for paraneoplastic neurological syndromes.J. Neurol. Neurosurg. Psychiatr. 2004; 75: 1135-1140
Henry, K., Paraneoplastic syndromes: definitions, classification, pathophysiology and principles of treatment.semin diagn pathol, 2019.36 (4): p. 204–210.
- Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.Journal of clinical oncology.Official J. Am. Soc. Clin. Oncol. 2008; 26: 4708-4713
Published online: March 21, 2020
Accepted: March 20, 2020
Received in revised form: March 17, 2020
Received: August 28, 2019
© 2020 Elsevier B.V. All rights reserved.